Clinical Trial Update: Low Dose Prolonged Infusion of Tissue Type Plasminogen Activator Therapy in Massive Pulmonary Embolism [Phase 4]

View source ↗

Summary

This document provides an update on a Phase 4 trial evaluating low-dose prolonged infusion of tissue plasminogen activator (tPA) for massive pulmonary embolism.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Embolism

Drugs mentioned

• Alteplase (Activase) (alteplase)

Snippet

Sponsor: Ahi Evren Chest and Cardiovascular Surgery Education and Research Hospital | Conditions: Pulmonary Embolism | Phase 4 | Status: UNKNOWN